UCL Centre for Clinical Microbiology, Division of Infection & Immunity, University College London, London, UK.
Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
BMJ Open Respir Res. 2023 Apr;10(1). doi: 10.1136/bmjresp-2022-001335.
The management of many chronic lung diseases involves multiple antibiotic prescriptions either to treat acute exacerbations or as prophylactic therapy to reduce the frequency of exacerbations and improve patients' quality of life.
To investigate the effects of antibiotics on the homeostasis of bacterial communities in the airways, and how this may contribute to antimicrobial resistance (AMR) among respiratory pathogens and microbiota.
Within an observational cohort study, sputum was collected from 84 patients with chronic obstructive pulmonary disease and/or bronchiectasis at stable state: 47 were receiving antibiotic prophylaxis therapy. V3-V4 16S-rRNA sequencing on Illumina MiSeq, quantitative PCR for typical respiratory pathogens, bacteriology cultures and antimicrobial susceptibility testing of sputum isolates, resistome analysis on a subset of 17 sputum samples using MinION metagenomics sequencing were performed.
The phylogenetic α-diversity and the total bacterial density in sputum were significantly lower in patients receiving prophylactic antibiotics (p=0.014 and 0.029, respectively). Antibiotic prophylaxis was associated with significantly lower relative abundance of respiratory pathogens such as , and members of family Enterobacteriaceae in the airway microbiome, but not and . No major definite directional shifts in the microbiota composition were identified with prophylactic antibiotic use at the cohort level. Surveillance of AMR and resistome analysis revealed a high frequency of resistance to macrolide and tetracycline in the cohort. AMR expressed by pathogenic bacterial isolates was associated with antibiotics prescribed as 'rescue packs' for prompt initiation of self-treatment of exacerbations (Spearman's rho=0.408, p=0.02).
Antibiotic prophylactic therapy suppresses recognised pathogenic bacteria in the sputum of patients with chronic lung disease. The use of antibiotic rescue packs may be driving AMR in this cohort rather than prophylactic antibiotics.
许多慢性肺部疾病的治疗需要开具多种抗生素处方,无论是用于治疗急性加重期还是预防治疗以减少加重频率并提高患者生活质量。
研究抗生素对气道细菌群落内稳态的影响,以及这如何导致呼吸道病原体和微生物组的抗微生物药物耐药性(AMR)。
在一项观察性队列研究中,在稳定期从 84 例慢性阻塞性肺疾病和/或支气管扩张症患者中收集痰:47 例正在接受抗生素预防治疗。对 Illumina MiSeq 进行 V3-V4 16S-rRNA 测序、对典型呼吸道病原体进行定量 PCR、对痰培养物进行细菌学培养和抗生素药敏试验、对 17 例痰样本中的一部分进行 MinION 宏基因组测序的耐药组分析。
接受预防性抗生素治疗的患者的痰中,系统发育 α 多样性和总细菌密度显著降低(p=0.014 和 0.029)。抗生素预防治疗与气道微生物组中呼吸道病原体的相对丰度显著降低相关,如 、 、肠杆菌科家族成员,但与 、 无关。在队列水平上,使用预防性抗生素并没有确定地改变微生物群的组成。对抗微生物药物耐药性和耐药组的监测显示,该队列中对大环内酯类和四环素的耐药率很高。从致病性细菌分离株表达的 AMR 与用于迅速开始自我治疗加重的“救援包”中开具的抗生素有关(Spearman's rho=0.408,p=0.02)。
抗生素预防治疗抑制了慢性肺部疾病患者痰中的已知致病性细菌。抗生素救援包的使用可能导致了该队列中的 AMR,而不是预防性抗生素。